Bellerophon Therapeutics (BLPH) Tops Q1 EPS by 75c

Bellerophon Therapeutics (NASDAQ: BLPH) reported Q1 EPS of $0.27, $0.75 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $5.64 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Bellerophon Therapeutics (BLPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c